We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Lilly, Boehringer-Ingelheim Bring a Second Diabetes Drug into the Cardiovascular Market
Lilly, Boehringer-Ingelheim Bring a Second Diabetes Drug into the Cardiovascular Market
Eli Lilly and partner Boehringer-Ingelheim scored a win in the cardiology arena this week, with the FDA’s approval of Jardiance (empagliflozin) for patients who have heart failure with reduced ejection fraction.